Multispectral optoacoustic tomography for in vivo detection of lymph node metastases in oral cancer patients using an EGFR-targeted contrast agent and intrinsic tissue contrast: A proof-of-concept study.

Autor:	Vonk J; Department of Oral & Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, the Netherlands., Kukačka J; Chair of Biological Imaging at the Central Institute for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich, Germany.; Institute of Biological and Medical Imaging, Helmholtz Zentrum München, Neuherberg, Germany., Steinkamp PJ; Department of Surgery, University of Groningen, University Medical Center Groningen, the Netherlands., de Wit JG; Department of Oral & Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, the Netherlands., Voskuil FJ; Department of Oral & Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, the Netherlands.; Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, the Netherlands., Hooghiemstra WTR; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., Bader M; Chair of Biological Imaging at the Central Institute for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich, Germany.; Institute of Biological and Medical Imaging, Helmholtz Zentrum München, Neuherberg, Germany., Jüstel D; Chair of Biological Imaging at the Central Institute for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich, Germany.; Institute of Biological and Medical Imaging, Helmholtz Zentrum München, Neuherberg, Germany.; Institute of Computational Biology, Helmholtz Zentrum München, Neuherberg, Germany., Ntziachristos V; Chair of Biological Imaging at the Central Institute for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich, Germany.; Institute of Biological and Medical Imaging, Helmholtz Zentrum München, Neuherberg, Germany., van Dam GM; Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.; AxelaRx / TRACER B.V., Groningen, the Netherlands., Witjes MJH; Department of Oral & Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, the Netherlands.
Jazyk:	angličtina
Zdroj:	Photoacoustics [Photoacoustics] 2022 Apr 29; Vol. 26, pp. 100362. Date of Electronic Publication: 2022 Apr 29 (Print Publication: 2022).
DOI:	10.1016/j.pacs.2022.100362
Abstrakt:	Oral cancer patients undergo diagnostic surgeries to detect occult lymph node metastases missed by preoperative structural imaging techniques. Reducing these invasive procedures that are associated with considerable morbidity, requires better preoperative detection. Multispectral optoacoustic tomography (MSOT) is a rapidly evolving imaging technique that may improve preoperative detection of (early-stage) lymph node metastases, enabling the identification of molecular changes that often precede structural changes in tumorigenesis. Here, we characterize the optoacoustic properties of cetuximab-800CW, a tumor-specific fluorescent tracer showing several photophysical properties that benefit optoacoustic signal generation. In this first clinical proof-of-concept study, we explore its use as optoacoustic to differentiate between malignant and benign lymph nodes. We characterize the appearance of malignant lymph nodes and show differences in the distribution of intrinsic chromophores compared to benign lymph nodes. In addition, we suggest several approaches to improve the efficiency of follow-up studies. Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests, . JK, MB, DJ, and VN received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme under grant agreement No 694968 (PREMSOT) and by the 10.13039/501100001659Deutsche Forschungsgemeinschaft (DFG), Sonderforschungsbereich-824 (SFB-824), subproject A1. VN is an equity owner and consultant at iThera Medical GmbH, member of the Scientific Advisory Board at SurgVision BV / Bracco Sp.A, owner at Spear UG, founder and consultant at I3, and founder of Sthesis. GMvD is CEO, founder and shareholder of TRACER Europe BV / AxelaRx. (© 2022 The Authors.)
Databáze:	MEDLINE
Externí odkaz: